Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Equity Income: 2022-2024

Historic Equity Income for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Dec 2024 value amounting to -$470,000.

  • Crinetics Pharmaceuticals' Equity Income was N/A to -$470,000 in Q1 2024 from the same period last year, while for Mar 2024 it was -$6.7 million, marking a year-over-year change of. This contributed to the annual value of -$470,000 for FY2024, which is 90.96% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Equity Income of -$470,000 as of FY2024, which was up 90.96% from -$5.2 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Equity Income high stood at -$470,000 for FY2024, and its period low was -$5.2 million during FY2023.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Equity Income value was -$1.0 million (recorded in 2022), while the average stood at -$2.2 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Equity Income crashed by 414.65% in 2023 and then surged by 90.96% in 2024.
  • Yearly analysis of 3 years shows Crinetics Pharmaceuticals' Equity Income stood at -$1.0 million in 2022, then crashed by 414.65% to -$5.2 million in 2023, then soared by 90.96% to -$470,000 in 2024.